The pathophysiology of atopic eczema

  title={The pathophysiology of atopic eczema},
  author={J P Allam and Natalija Novak},
  journal={Clinical and Experimental Dermatology},
  • J. Allam, N. Novak
  • Published 1 January 2006
  • Biology, Medicine
  • Clinical and Experimental Dermatology
Atopic eczema (AE) represents a pruritic chronic inflammatory skin disease with a complex background, triggered by genetic and environmental factors. Different dendritic cells subtypes, such as Langerhans cells, inflammatory dendritic epidermal cells and plasmacytoid dendritic cells, play a key role in AE and impact on the mechanisms underlying AE, such as the recruitment of inflammatory cells, T‐cell priming, and cytokine and chemokine release. In addition, allergens in combination with… 
In vivo evaluation of therapeutic options in atopic dermatitis
It is concluded that short-term intravenously administered treatment with mepolizumab has no clinical effect in AD patients, despite a significant decrease in peripheral blood eosinophils, and the preferred choice of phototherapy for AD should be NB UVB.
Contact allergy to ketoconazole cross‐sensitive to miconazole
with topical hydrocortisone, resulting in only minimal improvement. A diagnosis of interstitial pneumonia led to treatment with oral prednisolone, which resulted in improvement of the skin. However,
Effect of isoliquiritigenin for the treatment of atopic dermatitis-like skin lesions in mice
Isoliquiritigenin (ISLG) could be a potential therapeutic agent for the treatment of AD and could ameliorate the overall manifestation of AD-like symptoms including scratching behavior incidence and skin lesion severity.
The Ameliorative Effect of Adenophorae Radix on Atopic Dermatitis in vivo and in vitro
Treatment of AR attenuated the AD symptoms such as eczematous, erythema and dryness and serum IgE and IL-6 levels in AD model and inhibited the TNF-α-induced the Nuclear factor-κB activation in HaCaT cells.
Intracellular Cytokine Production in Children With Atopic Dermatitis: Effect of Levocetirizine Treatment
An immunoregulatory function for leveocetirizine is suggested by the present study, however such a claim may be more definitively made in future studies if trends established here prove consistent with larger sample number.
Cancer Concerns with Topical Immunomodulators in Atopic Dermatitis
An overview of the data that led to the approval by the FDA of a ‘black box’ warning for tacrolimus and pimecrolimus is provided and it is concluded that physicians, patients, and caregivers should feel confident about using these agents so long as they follow the FDA guidelines.
Atopic‐like dermatitis after secukinumab injection: A case report
A 70-year-old woman with intractable psoriasis vulgaris was treated with 300 mg of secukinumab and her skin eruption remarkably improved, fortunately, it was not severe and therefore treatable with just topicals and phototherapy.
Specific allergen immunotherapy for the treatment of atopic eczema.
Overall, the risk of bias was moderate, with high loss to follow up and lack of blinding as the main methodological concern, and the quality of the evidence was low.


Allergic and nonallergic forms of atopic diseases.
It is possible for the first time to delineate a new disease classification of allergic and nonallergic subtypes of atopic diseases, thereby bringing hope to the clinician for a more specific treatment approach for each subgroup of these patients.
New insights into atopic dermatitis.
This review summarizes recent progress in the understanding of the pathophysiology of atopic dermatitis and the implications for new management strategies.
A reducing microenvironment leads to the generation of FcepsilonRIhigh inflammatory dendritic epidermal cells (IDEC).
This study was able to increase the expression of a functional FcepsilonRI complex on the cell surface of immature monocyte-derived dendritic cells from atopic donors by creating a reducing microenvironment and enhance significantly the intracellular pool of the FcePSilonRIgamma chains.
Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions.
The results indicate that a positive APT reaction requires the presence of epidermal IgE(+) CD1a(+) cells in clinically noninvolved skin, but that also other, as yet unknown, discriminatory factors are involved.
A Reducing Microenvironment Leads to the Generation of FcεRIhigh Inflammatory Dendritic Epidermal Cells (IDEC)
This study was able to increase the expression of a functional FceRI complex on the cell surface of immature monocyte-derived dendritic cells from atopic donors by creating a reducing microenvironment and enhance significantly the intracellular pool of the FCERIγ chains, which is the limiting parameter for the Fceri surface expression.
Atopy patch test reactions show a rapid influx of inflammatory dendritic epidermal cells in patients with extrinsic atopic dermatitis and patients with intrinsic atopic dermatitis.
The DC alteration during skin lesion formation can be subdivided into early and late events, with the influx of IDECs as an early event and the alteration of the DC phenotype as a late event.
Enhanced expression of eotaxin and CCR3 in atopic dermatitis.
The enhanced local production of eotaxin may lead to the recruitment of eosinophils and T lymphocytes, which both express CCR3 and contribute to the initiation and maintenance of inflammation.
T regulatory cells in atopic dermatitis and subversion of their activity by superantigens.
Atopic dermatitis is associated with a low-producer transforming growth factor beta(1) cytokine genotype.
TGFB1 genotype may partly explain the strong genetic predisposition to AD, which is associated with hyperresponsiveness of lymphocytes to allergens.